Please select the option that best describes you:

Has the recently published SELECT trial of adjuvant erlotinib in early stage EGFR-mutant NSCLC impacted your management of these patients?   



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Northwest Georgia Oncology Centers
Great answer!
Medical Oncologist at Blue Ridge Cancer Care
Agree. There are strange scenarios when I have us...
Medical Oncologist at Kaiser Permanente
If they were asymptotic, would you have considered...
Sign in or Register to read more